Streetbeat News

Stock Prices

GH

Guardant Health's Shield blood test for colorectal cancer screening has received FDA approval, making it the first blood test approved as a primary screening option for CRC. This approval also meets Medicare coverage requirements, potentially increasing CRC screening rates in the U.S.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 10:31 am

ABT

RBGLY

Abbott Laboratories (NYSE:ABT) shares fell nearly 8% in pre-market trading after a U.S. jury imposed a $495 million penalty for a baby formula causing severe bowel disease. This verdict is part of nearly 1,000 lawsuits against Abbott and Reckitt Benckiser (OTC:RBGLY).

Portfolio Pulse from Benzinga Neuro

July 29, 2024 | 10:30 am

AAPL

AMZN

GOOGL

IBM

META

MSFT

QQQ

SPY

STM

TSLA

The upcoming week is crucial for tech stocks as major companies like Apple, Amazon, Microsoft, and Meta are set to report their earnings. Last week's earnings were mixed, with Tesla, Alphabet, and STMicroelectronics disappointing investors. However, IBM saw positive reactions due to strong AI bookings. Analysts are optimistic about the tech sector's future, especially with significant AI investments expected. The Invesco QQQ Trust and SPDR S&P 500 ETF Trust showed mixed performance last week.

Portfolio Pulse from Shanthi Rexaline

July 29, 2024 | 10:25 am

CNA

CNA Financial (NYSE:CNA) reported strong Q2 earnings, with EPS of $1.67 beating the $1.23 estimate and sales of $4.27B surpassing the $3.55B estimate. This represents significant year-over-year growth in both earnings and sales.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 10:17 am

MRIN

Marin Software reported preliminary Q2 2024 revenue of $4M, down from $4.4M YoY. The company estimates a GAAP loss from operations between $2.3M and $2.1M, an improvement from $6.0M YoY. Non-GAAP loss is estimated between $1.9M and $1.7M, also an improvement from $4.8M YoY. Cash balance stands at $7.9M.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 10:08 am

RVTY

Revvity has updated its 2024 adjusted EPS guidance to a range of $4.70-$4.80, up from the prior guidance of $4.55-$4.75 and above the consensus estimate of $4.63.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 10:07 am

IART

Integra LifeSciences has updated its FY24 revenue and adjusted EPS expectations to $1.609B-$1.629B and $2.41-$2.57, respectively, down from prior estimates. The revised outlook reflects quality and compliance issues and significant investments in improvements.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 10:06 am

IART

Integra LifeSciences has revised its Q3 2024 revenue expectations to $372M-$382M, significantly below the $432.11M estimate. Adjusted EPS is expected to be $0.36-$0.44, also below the $0.85 estimate. For the full year 2024, the company expects revenue of $1.609-$1.629 billion and adjusted EPS of $2.41-$2.57.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 10:03 am

LILM

Lilium has filed for a mixed shelf offering of up to $250 million, which could include various types of securities such as common stock, preferred stock, debt securities, and warrants.

Portfolio Pulse from charles@benzinga.com

July 29, 2024 | 10:03 am

NUTX

Nutex Health Inc. (NASDAQ:NUTX) has regained compliance with Nasdaq's minimum bid price requirement following a 1:10 reverse stock split. The company's stock traded above $1.00 per share from July 3, 2024, to July 23, 2024, resolving the prior bid price deficiency.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 9:31 am